Marker half-life analysis as a prognostic tool in testicular cancer.

[1]  P. Lange,et al.  Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules. , 1980, The American journal of medicine.

[2]  P. Lange,et al.  Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stge III testicular cancer. , 1980, Cancer treatment reports.

[3]  J. Haddow,et al.  Serial monitoring of serum alpha‐fetoprotein and chorionic gonadotropin in males with germ cell tumors , 1979, Cancer.

[4]  J. Kohn.  The Dynamics of Serum Alpha‐fetoprotein in the Course of Testicular Teratoma , 1978 .

[5]  P. Lange,et al.  Surgical treatment of stage I and stage II nonseminomatous testicular cancer in adults. , 1977, The Urologic clinics of North America.

[6]  M. Samuels,et al.  Bleomycin combination chemotherapy in the management of testicular neoplasia , 1975, Cancer.

[7]  T. Waldmann,et al.  Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. , 1972, Lancet.

[8]  G T Ross,et al.  A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. , 1972, American journal of obstetrics and gynecology.

[9]  E. Gurpide,et al.  Metabolism of HCG in man. , 1969, The Journal of clinical endocrinology and metabolism.

[10]  D. Gitlin,et al.  Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus. , 1966, The Journal of clinical investigation.